Coloplast stock holds after fiscal Q3 margin setback
Published on 09/01/2026 at 15:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast A/S (ISIN DK0060448595) stock is trading close to its latest closing level as investors digest fiscal Q3 2026 results released in August 2026, where revenue grew but margins came under pressure from the ongoing Kerecis integration. As of August 28, 2026, the shares closed at DKK462.70 on Nasdaq Copenhagen, with the price standing 5.49% higher year to date and 15.32% below the start of 2025 according to a detailed market overview covering Coloplast stock.
Fiscal Q3 2026 results reshape expectations
Per a recent earnings recap dated August 18, 2026, Coloplast reported fiscal Q3 2026 revenue that beat prior expectations, while margins missed consensus as the company absorbed costs linked to the Kerecis acquisition. The commentary highlights that revenue in fiscal Q3 2026 came in ahead of market forecasts, confirming continued top-line growth compared with the same quarter of fiscal 2025, whereas profitability metrics lagged, reflecting integration and investment effects described in the fiscal Q3 2026 news summary.
An update dated August 19, 2026 notes that earnings models have been adjusted following the release, with revised EPS forecasts after fiscal Q3 2026. The same analysis mentions an average price target of DKK469.38 versus the closing price of DKK462.70 on August 28, 2026, implying upside of 1.44% at that time and offering a quantified benchmark for investors tracking valuation based on expected earnings, as shown in the earnings and price-target overview.
Valuation and index context for Coloplast stock
The same market-data profile situates Coloplast within major European benchmarks, including the STOXX Europe 600 index, confirming its role as a large-cap healthcare name in the region. With the share price at DKK462.70 on August 28, 2026 and an average target of DKK469.38, the stock traded just below consensus fair value, while the 5.49% gain since the beginning of 2026 contrasted with the negative performance recorded since January 2025, underlining how sentiment has improved in the current year compared with the previous period based on recent index-component data.
For investors, the key takeaway from fiscal Q3 2026 is that Coloplast is delivering higher revenue while margins remain under pressure, a combination that feeds directly into earnings forecasts and valuation multiples. The modest gap between the DKK462.70 closing price and the DKK469.38 average target, together with the 5.49% year-to-date gain and the longer-term decline since early 2025, encapsulates a balanced picture where growth prospects and integration costs both play a role in how Coloplast stock is priced in the market, as reflected in the latest performance chart.
Ostomy and continence care remain core businesses
Beyond the numbers, Coloplast is widely known for its ostomy and continence care products, which form the backbone of its medical devices portfolio. The company develops ostomy bags, baseplates, and accessories designed to help patients manage life after ostomy surgery, as well as catheters and other continence care solutions used in hospitals and home care settings, according to the issuer profile presented on its investor-focused pages on the Coloplast investor relations site.
These product lines are central to Coloplast's revenue base and underpin the demand trends discussed in recent earnings commentary, where higher volumes and new product introductions contribute to top-line growth even as integration-related costs weigh on margins. For investors, understanding how ostomy and continence care drive recurring revenue and interact with newer acquisitions such as Kerecis is important when assessing the sustainability of the fiscal Q3 2026 revenue beat alongside the margin miss highlighted in segment performance discussions.
Coloplast stock price context in late August 2026
Coloplast shares trade on Nasdaq Copenhagen under the ticker COLO B, with the latest available closing price at DKK462.70 on August 28, 2026, as detailed in the recent market-data snapshot covering the August 28, 2026 quote. That closing level places the stock just below the DKK469.38 average price target, and the 5.49% gain since the start of 2026 suggests a steady recovery phase within the longer-term context of a 15.32% decline since January 2025.
As of August 28, 2026, this combination of modest year-to-date gains, a still-negative multi-year performance, and consensus targets only slightly above the market price illustrates why fiscal Q3 2026 margin trends and the Kerecis integration are drawing close attention. Coloplast stock, listed in Denmark and included in key European healthcare indexes, offers investors exposure to chronic-care medical devices, with the current price and valuation metrics tied closely to how quickly earnings can catch up with revenue growth following the latest quarter.
Read more
Further quantitative details on Coloplast stock, including historical performance, analyst estimates, and segment commentary linked to the fiscal Q3 2026 report, can be found in the comprehensive quote and news overview that aggregates data and news on Coloplast A/S, as well as through the company-focused materials provided on the official investor relations homepage where Coloplast shares presentations and reports.
Ostomy care product example
A representative Coloplast product within its ostomy portfolio is the ostomy bag system designed for patients living with a stoma after colorectal or bladder surgery. These systems typically combine a soft, skin-friendly baseplate with a secure pouch engineered to minimize leaks and odors, enabling patients to maintain mobility and confidence in daily life, as presented in the product information accessible via the company website which also outlines key product categories. Such devices illustrate how Coloplast's medical solutions translate into recurring demand in hospitals and home care and underpin the revenue trends that fed into the fiscal Q3 2026 results.
Closing view on Coloplast stock
Coloplast stock on Nasdaq Copenhagen closed at DKK462.70 as of August 28, 2026, based on the latest detailed quote snapshot summarizing the August 28, 2026 session. In the context of fiscal Q3 2026 revenue growth, margin pressure from the Kerecis integration, and an average price target of DKK469.38, that price level places Coloplast stock just below consensus expectations while showing a positive performance in 2026 against a still-weak longer-term chart.
Fact box
Company: Coloplast A/S
ISIN: DK0060448595
Ticker: COLO B
Exchange: Nasdaq Copenhagen
Price (as of August 28, 2026, 5:20 p.m. local time): DKK462.70
Market cap: Data provided in recent quote overviews for Coloplast A/S
Sector / Industry: Healthcare - Medical devices
Index membership: STOXX Europe 600 and relevant Danish equity indexes
